Frequent Coamplification and Cooperation between C-MYC and PVT1 Oncogenes Promote Malignant Pleural Mesothelioma

July 11, 2014 | Comments Off on Frequent Coamplification and Cooperation between C-MYC and PVT1 Oncogenes Promote Malignant Pleural Mesothelioma

Journal of Thoracic Oncology. 2014 July. [Link] Lin HY, Mino B, Rice DC, Riquelme E, Rodriguez J, Suraoker MB, Tsao A, Wistuba Il. Abstract Introduction Malignant pleural mesothelioma (MPM) is…

B7-H1 Expression in Malignant Pleural Mesothelioma is Associated with Sarcomatoid Histology and Poor Prognosis

July 10, 2014 | Comments Off on B7-H1 Expression in Malignant Pleural Mesothelioma is Associated with Sarcomatoid Histology and Poor Prognosis

Journal of Thoracic Oncology. 2014 July. [Link] Dong H, Harrington SM, Krco CJ, Kwon ED, Mansfield AS,Peikert T, Roden AC, Sheinin YM. Abstract Introduction B7 homolog 1 (B7-H1; aka programmed…

6-Thioguanine: A Drug With Unrealized Potential for Cancer Therapy

July 9, 2014 | Comments Off on 6-Thioguanine: A Drug With Unrealized Potential for Cancer Therapy

The Oncologist. 2014 June 13. [Epub ahead of print] [Link] Bertino JR, Lubin M, Munshi PN. Abstract Sixty years ago, 6-thioguanine (6-TG) was introduced into the clinic. We suggest its…

Germline Mutation of Bap1 Accelerates Development of Asbestos-Induced Malignant Mesothelioma

July 8, 2014 | Comments Off on Germline Mutation of Bap1 Accelerates Development of Asbestos-Induced Malignant Mesothelioma

Cancer Research. 2014 June 13. [Epub ahead of print] [Link] Cai KQ, Cheung M, Kadariya Y, Karar J, Litwin S, Menges CW, Pei J, Peng H, Rauscher FJ, Sementino E,…

Carbonic Anhydrase IX (CAIX) Does Not Differentiate Between Benign and Malignant Mesothelium

July 7, 2014 | Comments Off on Carbonic Anhydrase IX (CAIX) Does Not Differentiate Between Benign and Malignant Mesothelium

American Journal of Clinical Pathology. 2014 July. [Link] Ananthanarayanan V, Antic T, FRCPath, Husain AN, Krausz T, Tretiakova M. Abstract Objectives To examine carbonic anhydrase IX (CAIX), a marker of…

Phase 1 study of the antimesothelin immunotoxin SS1P in combination with pemetrexed and cisplatin for front-line therapy of pleural mesothelioma and correlation of tumor response with serum mesothelin, megakaryocyte potentiating factor, and cancer antigen 125

July 7, 2014 | Comments Off on Phase 1 study of the antimesothelin immunotoxin SS1P in combination with pemetrexed and cisplatin for front-line therapy of pleural mesothelioma and correlation of tumor response with serum mesothelin, megakaryocyte potentiating factor, and cancer antigen 125

Cancer. 2014 July 2. [Epub ahead of print] [Link] Hassan R, Hollevoet K, Kreitman RJ, Ling A, Miettinen M, Pastan I, Sharon E, Steinberg SM, Thomas A, Zhang J. Abstract…

Third-space fluid distribution of pemetrexed in non-small cell lung cancer patients

July 6, 2014 | Comments Off on Third-space fluid distribution of pemetrexed in non-small cell lung cancer patients

Cancer Chemotherapy and Pharmacology. 2014 June 17. [Epub ahead of print] [Link] Hansen SH, Honore PH, Joensen SJ, Mellemgaard A, Olsen M. Abstract Aim Hydrophilic drugs particularly those with low…

ERCC1 as a Biological Marker Guiding Management in Malignant Pleural Mesothelioma

July 5, 2014 | Comments Off on ERCC1 as a Biological Marker Guiding Management in Malignant Pleural Mesothelioma

Asian Pacific Journal of Cancer Prevention. 2014. [Link] Arslan A, Baran M, Cihan YB, Deniz K, Karaca H, Ozturk A. Abstract Background: To determine prognostic value of excision repair cross-complementation…

Tumors that mimic asbestos-related mesothelioma: time to consider a genetics-based tumor registry?

July 4, 2014 | Comments Off on Tumors that mimic asbestos-related mesothelioma: time to consider a genetics-based tumor registry?

Frontiers in Genetics. 2014 May 30. [Link] Galbraith DA, James RC, Kerger BD. Abstract The diagnosis of mesothelioma is not always straightforward, despite known immunohistochemical markers and other diagnostic techniques.…

Pemetrexed and communicating hydrocephalus

July 3, 2014 | Comments Off on Pemetrexed and communicating hydrocephalus

The Ochsner Journal. 2014 Summer. [Link] Mott FE & Son CO. Abstract Background Pemetrexed (Alimta) is widely used in combination with platinum as a first-line treatment of mesothelioma and adenocarcinoma…

Categories